(4-氯苯甲酰基)乙酸乙酯 | 2881-63-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (4-氯苯甲酰基)乙酸乙酯
• 中文别名: 3-(4-氯苯基)-3-氧丙酸乙酯；3-(4-氯苯基)-3-氧-丙酸乙酯
• 英文名称: ethyl (4-chlorobenzoyl)acetate
• 英文别名: ethyl 4-benzoylacetate；ethyl 3-(4-chlorophenyl)-3-oxopropanoate
• CAS: 2881-63-2
• 化学式: C₁₁H₁₁ClO₃
• mdl: MFCD00018713
• 分子量: 226.66
• InChiKey: DGCZHKABHPDNCC-UHFFFAOYSA-N

物化性质

• 熔点：
  38 °C(Solv: ethanol (64-17-5))
• 沸点：
  268-269 °C(lit.)
• 密度：
  1.218 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 溶解度：
  溶于丙酮
• 稳定性/保质期：

  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2918300090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  常温下应存放在阴凉、通风的地方。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Ethyl (4-chlorobenzoyl)acetate
CAS-No. : 2881-63-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C11H11ClO3
Molecular Weight : 226,66 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 37 - 40 °C
point
f) Initial boiling point and 268 - 269 °C
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,218 g/mL at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备

3-(4-氯苯基)-3-氧-丙酸乙酯可通过4-氯苯甲酸作为原料进行制备。

将4-氯苯甲酸（30.0g，0.192mol）溶解在二氯甲烷（DCM, 250mL）中。随后加入草酰氯（25mL，0.288mol），并逐滴添加DMF（0.5mL）。将反应混合物回流2小时后，在真空下浓缩得到黄色液体的酰氯。

接着，向丙二酸乙酯钾（41g，0.241mol）在乙腈（537mL）中的溶液中加入三乙胺（TEA, 67mL）。将该混合物冷却至冰-盐浴，并逐渐加入无水氯化镁（MgCl₂, 27.4g，0.288mol），在该温度下搅拌3小时。之后，向其中加入上述制备的酰氯，反应混合物升温至室温并搅拌过夜。

冷却后的混合物中缓慢滴加2N HCl（600mL），然后在冰浴中继续搅拌1.5小时。将此溶液转移到分液漏斗中，并用乙酸乙酯（3×200mL）萃取。合并的有机层经饱和碳酸氢钠（450mL）、盐水（250mL）洗涤，再用无水硫酸钠干燥、过滤后，在真空下浓缩得到粗产物3-(4-氯苯基)-3-氧-丙酸乙酯（48.6g）。此产物无需进一步纯化。

用途

3-(4-氯苯基)-3-氧-丙酸乙酯是一种羧酸酯类有机化合物，可用作医药中间体。已有文献报道其可用于制备BET抑制剂。

反应信息

• 作为反应物：
  描述：

  (4-氯苯甲酰基)乙酸乙酯 在 氢氧化钾 作用下， 生成 对氯苯乙酮
  参考文献：
  名称：

  Thorp; Brunskill, Journal of the American Chemical Society, 1915, vol. 37, p. 1262

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 3-hydroxy-3-(4-chlorophenyl)propanoate 在 重铬酸 作用下， 以 乙醚 为溶剂， 反应 4.0h， 以75%的产率得到(4-氯苯甲酰基)乙酸乙酯
  参考文献：
  名称：

  通过Ru（II）-BINAP催化的不对称加氢合成（R）-（-）-baclofen的对映选择性

  摘要：

  已经描述了一种短而有效的对映选择性合成（R）-（-）-baclofen（一种选择性的GABA B激动剂）的方法，其总收率为ee的26％和90％。Ru（II）–（S）-BINAP催化CC和CO基团的不对称氢化反应是将立体异构中心引入分子的关键步骤。

  DOI：

  10.1016/s0957-4166(03)00024-7
• 作为试剂：
  描述：

  (4-氯苯甲酰基)乙酸乙酯 、 磺酰氯 在 (4-氯苯甲酰基)乙酸乙酯 作用下， 以 氯仿 为溶剂， 反应 6.0h， 以to give 49.0 g of crude ethyl 2-chloro-p-chlorobenzoylacetate的产率得到2',4'-二氯苯甲酰基乙酸乙酯
  参考文献：
  名称：

  2-Amino-4-substituted-thiazolecarboxylic acids and their derivatives

  摘要：

  2-氨基-4-取代-5-噻唑羧酸及其衍生物是制备具有除草安全剂作用的2-取代-4-取代-5-噻唑羧酸衍生物的中间体。

  公开号：

  US04308391A1

文献信息

• [EN] THERAPEUTIC METHODS<br/>[FR] PROCÉDÉS THÉRAPEUTIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013025992A1

  公开（公告）日：2013-02-21

  The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents

  本发明涉及一种治疗丙型肝炎的方法，包括在需要的人体内给予本文描述的II式或IIB式化合物或其药用盐与一种或多种替代丙型肝炎治疗药物的组合治疗
• Glutamate as an Efficient Amine Donor for the Synthesis of Chiral β‐ and γ‐Amino Acids Using Transaminase
  作者：Geon‐Hee Kim、Hyunwoo Jeon、Taresh P. Khobragade、Mahesh D. Patil、Sihyong Sung、Sanghan Yoon、Yumi Won、Sharad Sarak、Hyungdon Yun

  DOI：10.1002/cctc.201802048

  日期：2019.3.6

  A recyclable glutamate amine donor system employing transaminase (TA), glutamate dehydrogenase (GluDH) and mutant formate dehydrogenase (FDHm) was developed, wherein amine donor Glu was regenerated using GluDH and thereby circumvented the inhibition of TA by α‐ketoglutarate. Various enantiopure β‐, γ‐amino acids, and amines were successfully synthesized with high conversions and excellent enantiomeric

  开发了一种利用转氨酶（TA），谷氨酸脱氢酶（GluDH）和突变型甲酸脱氢酶（FDHm）的可回收谷氨酸胺供体系统，其中使用GluDH再生了胺供体Glu，从而避免了α-酮戊二酸对TA的抑制作用。使用该系统成功合成了各种对映体纯的β-，γ-氨基酸和胺，具有高转化率和出色的对映体过量。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• Aqueous CO₂ fixation: construction of pyridine skeletons in cooperation with ammonium cations
  作者：Shiqun Xiang、Weibin Fan、Wei Zhang、Yinghua Li、Shiwei Guo、Deguang Huang

  DOI：10.1039/d1gc02303a

  日期：——

  synthesis of fused pyridines by [2 + 2 + 1 + 1] the cycloaddition of ketones with an ammonium cation under a CO2 atmosphere. The reactions employed ammonium cation as a nitrogen source and CO2 gas as a carbon source in an aqueous solution. Monoethanolamine (MEA) was used as an additive to increase the solubility of CO2 in an aqueous solution. The scope and versatility of the method are demonstrated with 38

  通过 [2 + 2 + 1 + 1] 酮与铵阳离子在 CO 2气氛下的环加成，探索了一种简单且绿色的合成稠合吡啶的方法。该反应在水溶液中使用铵阳离子作为氮源和CO 2气体作为碳源。单乙醇胺（MEA）用作添加剂以增加CO 2在水溶液中的溶解度。该方法的范围和多功能性通过 38 个示例进行了演示。发现产品具有光敏性，并显示出作为有机光电材料的潜在应用。在实验研究的基础上提出了一种selectfluor促进的反应机理。我们的工作非常出色，因为它是一个不含金属的系统，使用 CO 2 作为碳源和 MEA 作为水性合成中的添加剂。
• HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
  申请人：McCall John M.

  公开号：US20120277224A1

  公开（公告）日：2012-11-01

  Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

  本文披露了新的杂环化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了抑制PAS激酶（PASK）在人类或动物主体中活性的方法，用于治疗疾病，如糖尿病。